Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum BioVaxys Technology Corp. C.BIOV

Alternate Symbol(s):  BVAXF

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical... see more

CSE:BIOV - Post Discussion

BioVaxys Technology Corp. > BIOV & PAPILOCARE
View:
Post by moneywagon on Jan 18, 2023 11:43am

BIOV & PAPILOCARE

ooops sorry sorry type "o" last post PAPILOCARE! We only need to disburse & collect revenues!
NOW, Give it to me right in the kisser FDA, give us the approval news and knock my socks off with that FDA approval! tic toc
Comment by sunmist10000 on Jan 20, 2023 3:33pm
I bought a few shares in this company at around 40 cents a few years ago.  It has done nothing but go down.   Can some let me know if this is a genuine company that is developing new drugs and doing a lot of good research.  The price action would indicate that this amy be a pump and dump company.
Comment by 1DoxieDollar on Jan 24, 2023 11:43am
Yes, a very genuine company.  Multiple patents & patent applications, human data in >600 patients from their first generation cancer vaccine (much of it published in quality peer reviewed journals), an expandable cancer vaccine platform for other tumors (again, w/ published data), US distribution rights for the leading EU product for (HPV related) cervical lesions, university research ...more  
Comment by sunmist10000 on Jan 30, 2023 4:26pm
Terrific.  Nice to know that.  Thanks
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities